All In Biotech

Drug Trial Radar · NCT07690189

Study of NTB-928 in R/R OC

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FRα-Targeting Bispecific T Cell Engager, in Subjects With Relapsed/Refractory Ovarian Carcinoma

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jun 29, 2026

Primary completion

Jun 2028

Study completion Feb 2029

Sponsor

Lead sponsor
TeneoSeven, Inc.Industry
Sponsor type
Industry
First posted
Jul 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study will also look for early signs of anti-cancer activity of NTB-928. The main questions the study aims to answer are: * What side effects do participants experience when receiving NTB-928, including side effects that limit how much of it can be safely given? * How is NTB-928 processed by the body at different dose levels? * Does the immune system react to NTB-928 during treatment? * What dose of NTB-928 can be given safely that shows early signs of activity against ovarian cancer?

Conditions

  • Relapsed/Refractory Ovarian Carcinoma

Interventions

  • NTB-928Drug

    NTB-928 is an investigational study drug administered as an intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of dose-limiting toxicities (DLTs) within the first cycle of treatment with NTB-928Time frame: Up to 35 days
  2. Number of participants with adverse events (AEs) and serious adverse events (SAEs), by severity and relatedness to NTB-928Time frame: Up to approximately 3 years
  3. Maximum plasma concentration (Cmax)Time frame: Up to approximately 3 years
  4. Time to Cmax (Tmax)Time frame: Up to approximately 3 years
  5. Area under the plasma concentration-time curve (AUC) over the dosing interval (AUC0-T)Time frame: Up to approximately 3 years
  6. AUC from time zero to time t (AUC0-t)Time frame: Up to approximately 3 years
  7. AUC from time 0 extrapolated to infinity (AUC0-∞)Time frame: Up to approximately 3 years
  8. Terminal elimination half-life (t½)Time frame: Up to approximately 3 years
  9. Clearance (CL)Time frame: Up to approximately 3 years
  10. Terminal elimination rate constant (λz)Time frame: Up to approximately 3 years
  11. Volume of distribution (Vz)Time frame: Up to approximately 3 years
  12. Accumulation ratio (Rac) for Cmax and AUC, and trough concentration (Ctrough)Time frame: Up to approximately 3 years
  13. Number of participants with anti-drug antibodies (ADA) at baseline and after treatmentTime frame: Up to approximately 3 years

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Alabama

    Birmingham, Alabama · Recruiting

  • University of California San Francisco Health - Hereditary Cancer Clinic - Mission Bay

    San Francisco, California · Recruiting

  • University of Colorado Anschutz Cancer Center - Anschutz Cancer Pavilion

    Aurora, Colorado · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • START Northwell, LLC

    Lake Success, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.